Literature DB >> 16004175

Actinomycosis esophagitis in a patient with persistent dysphagia.

Semaan Georges Kosseifi1, Kim Dittus, Dima N Nassour, Mohammad Axis Shaikh, Mark F Young.   

Abstract

Many causes of esophagitis exist in immunocompromised patients. Uncommon pathogens must be considered to facilitate timely and appropriate therapy. A limited number of cases of esophageal actinomycosis have been reported. This report describes an unusual case of esophageal actinomycosis in a patient with persistent dysphagia. The broad differential may have delayed definitive diagnosis in the case study patient. Biopsy and culture are essential for accurate diagnosis. Although actinomycosis is a rare disease, it should be included in the differential diagnosis of patients presenting with oral or esophageal complaints. It may also be considered as an opportunistic infection in immunocompromised patients. The treatment of choice is parenteral penicillin G, 18 to 24 million units for 2 to 6 weeks followed by oral therapy for 6-12 months.

Entities:  

Mesh:

Year:  2005        PMID: 16004175     DOI: 10.1097/01.SMJ.0000163312.19136.47

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Esophageal actinomycosis: a case report and review of radiographic findings.

Authors:  Rodney D Welling; Diana M Cardona; William M Thompson
Journal:  J Radiol Case Rep       Date:  2009-12-01

2.  A case of esophageal actinomycosis with a unique morphology presenting as a refractory ulcer.

Authors:  Sho Fukuda; Noboru Watanabe; Takahiro Domen; Mitsuaki Ishioka; Masayuki Sawaguchi; Reina Ohba; Hisashi Shiga; Tamotsu Matsuhashi; Mario Jin; Katsunori Iijima
Journal:  Clin J Gastroenterol       Date:  2017-11-09

Review 3.  Esophageal actinomycosis in a fifty-three-year-old man with HIV: case report and review of the literature.

Authors:  Erin M Murchan; Gil Redelman-Sidi; Minal Patel; Christopher Dimaio; Susan K Seo
Journal:  AIDS Patient Care STDS       Date:  2010-02       Impact factor: 5.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.